Life Healthcare

lifehealthcare.co.za

The Life Healthcare Group is a key role-player in the South African healthcare sector and is listed on the Johannesburg Stock Exchange (JSE). Our primary business is private acute hospital care. With 63 healthcare facilities, our group has one of the most extensive footprints in southern Africa. Life Healthcare is the first and only hospital group to have achieved multi-site ISO 9001 certification. Our international division includes the Group’s investment in Max Healthcare, an acute care hospital business in India and Scanmed Multimedis, a leading healthcare provider in Poland.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

MILLIPORESIGMA INVESTS $ 286 MILLION IN U.S. DRUG SAFETY TESTING CAPACITY

MilliporeSigma | November 16, 2022

news image

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that its Life Science business sector is investing more than $ 286 million in its biosafety testing capacity at the company's site in Rockville, Maryland, USA. This will significantly increase the company's ability to conduct biosafety testing and analytical development services. Biosafety testing and analytical development are critical and fund...

Read More

Pharmacy Market

IONIS ENTERS COLLABORATION TO ADVANCE NEXT GENERATION PROGRAM TARGETING LP(A) FOR CARDIOVASCULAR DISEASE

PRNewswire | August 04, 2023

news image

Ionis Pharmaceuticals, Inc. announced that it has entered a collaboration and license agreement with Novartis for the discovery, development and commercialization of a novel medicine for patients with lipoprotein(a), or Lp(a)-driven cardiovascular disease (CVD). This builds on the companies' existing collaboration focused on the development and commercialization of pelacarsen, which Novartis is currently evaluating in a Phase 3 cardiovascular outcome study. The next generation compound...

Read More

Business Insights

KARO PHARMA ACQUIRES OTC BRAND PORTFOLIO FROM TEVA PHARMACEUTICALS

Karo Pharma, Teva Pharmaceuticals | February 04, 2021

news image

Karo Pharma Aktiebolag ("Karo") today reports the securing of an OTC brand portfolio containing Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva Pharmaceuticals (Teva) for an absolute thought of EUR 84m. The exchange moves responsibility for brand portfolio, included Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva to Karo. The brands created deals barely shy of EUR 35m in 202...

Read More

Business Insights

HARROW HEALTH ACQUIRES OPHTHALMIC SURGICAL DRUG CANDIDATE FROM WAKAMOTO PHARMACEUTICAL CO., LTD.

Harrow Health, Inc. | August 18, 2021

news image

Harrow Health, Inc. an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights for drug candidate MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection. MAQ-100 is marketed and sold by Wakamoto in Japan as MaQaid®. Following Japan’s Ministry of Health Labor and Welfare (or MHLW) approval, MaQaid was launched in Japan in 2010, ...

Read More
news image

Business Insights

MILLIPORESIGMA INVESTS $ 286 MILLION IN U.S. DRUG SAFETY TESTING CAPACITY

MilliporeSigma | November 16, 2022

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that its Life Science business sector is investing more than $ 286 million in its biosafety testing capacity at the company's site in Rockville, Maryland, USA. This will significantly increase the company's ability to conduct biosafety testing and analytical development services. Biosafety testing and analytical development are critical and fund...

Read More
news image

Pharmacy Market

IONIS ENTERS COLLABORATION TO ADVANCE NEXT GENERATION PROGRAM TARGETING LP(A) FOR CARDIOVASCULAR DISEASE

PRNewswire | August 04, 2023

Ionis Pharmaceuticals, Inc. announced that it has entered a collaboration and license agreement with Novartis for the discovery, development and commercialization of a novel medicine for patients with lipoprotein(a), or Lp(a)-driven cardiovascular disease (CVD). This builds on the companies' existing collaboration focused on the development and commercialization of pelacarsen, which Novartis is currently evaluating in a Phase 3 cardiovascular outcome study. The next generation compound...

Read More
news image

Business Insights

KARO PHARMA ACQUIRES OTC BRAND PORTFOLIO FROM TEVA PHARMACEUTICALS

Karo Pharma, Teva Pharmaceuticals | February 04, 2021

Karo Pharma Aktiebolag ("Karo") today reports the securing of an OTC brand portfolio containing Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva Pharmaceuticals (Teva) for an absolute thought of EUR 84m. The exchange moves responsibility for brand portfolio, included Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva to Karo. The brands created deals barely shy of EUR 35m in 202...

Read More
news image

Business Insights

HARROW HEALTH ACQUIRES OPHTHALMIC SURGICAL DRUG CANDIDATE FROM WAKAMOTO PHARMACEUTICAL CO., LTD.

Harrow Health, Inc. | August 18, 2021

Harrow Health, Inc. an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights for drug candidate MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection. MAQ-100 is marketed and sold by Wakamoto in Japan as MaQaid®. Following Japan’s Ministry of Health Labor and Welfare (or MHLW) approval, MaQaid was launched in Japan in 2010, ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us